# IGF-1 DES

> IGF-1 DES is a truncated form of insulin-like growth factor 1 missing the first three amino acids of the N-terminus, a modification that markedly reduces its affinity for IGF-binding proteins. This gives it substantially greater potency at the IGF-1 receptor relative to native IGF-1, but only for a very short window, since it is cleared from circulation quickly. It is studied primarily for localized, site-specific muscle growth when injected directly into a trained muscle. Human clinical data are limited, and most supporting evidence comes from animal and in vitro studies.

- URL: https://www.lifeconverted.com/peptides/igf-1-des
- Also known as: Des(1-3) IGF-1, DES IGF-1
- Primary category: Muscle & Performance
- Effectiveness rank: #16 in Healing & Recovery; #3 in Muscle & Performance
- Evidence level: Emerging research
- Route: Intramuscular (Typically injected directly into the trained muscle immediately after exercise because of its very short half-life; some protocols use subcutaneous injection instead.)
- Dose range: 20-60 mcg
- Dose tiers: low 20 mcg; moderate 40 mcg; high 60 mcg
- Half-life: Approximately 20-30 minutes
- Timing: ~20 min before a workout
- Cycle: 4-6 weeks on, 4-6 weeks off (Because of its localized, acute action, cycling is typically framed around training blocks rather than continuous administration.)
- Storage: Store lyophilized powder frozen; once reconstituted with bacteriostatic water, keep refrigerated and use within 1-2 weeks given its potency-sensitive nature.

## Mechanism of action

By removing the binding-protein-interacting N-terminal residues, IGF-1 DES remains largely free and unbound in tissue, allowing it to activate the IGF-1 receptor and downstream PI3K/Akt/mTOR signaling with greater immediate potency than native IGF-1. Its rapid clearance means this activation is brief and localized, which is why it is typically injected directly at the target muscle rather than administered systemically.

## Reported benefits

- High potency at the IGF-1 receptor per unit dose
- Proposed localized hypertrophic effect at the injection site
- Short duration of action may allow more precise timing around training sessions

## Reported side effects

- Localized swelling or discomfort at the injection site
- Hypoglycemia risk, particularly if combined with insulin
- Theoretical concern for promoting abnormal cell growth given potent growth-factor activity
- Very short half-life limits the window for effect, which some view as a practical drawback

## Common protocols

- Post-workout intramuscular injection directly into the trained muscle

## Stacking notes

Often discussed alongside IGF-1 LR3 in research contexts, with DES used acutely around training and LR3 used for sustained systemic exposure; no controlled human data support a specific combined protocol.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer